2 Upcoming FDA Approval Decisions That Investors Should Really Watch

·2-min read

In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting